Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial (VELO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05468892 |
|
Recruitment Status :
Completed
First Posted : July 21, 2022
Last Update Posted : February 1, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Metastatic Colon Cancer | Drug: Trifluridine Tipiracil Drug: Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX] | Phase 2 |
This is a randomized phase II, open label, two arm study, evaluating the efficacy of panitumumab in combination with Trifluridine-Tipiracilas third line therapy, after a first line containing an anti-EGFR agent panitumumab(at least 70% of study population) or cetuximab. The primary objective is to evaluate the efficacy [as defined by progression free survival (PFS)] of panitumumab in combination with Trifluridine-Tipiracil in pretreated mCRC patients. The secondary objective is to evaluate the objective response rate (ORR), overall survival (OS) and safety. Patients will be randomized in a 1:1 ratio to receive:
Arm A: Trifluridine-Tipiracil Arm B: Panitumumab + Trifluridine-Tipiracil A total of 112 patients will be enrolled. Treatment will be administered in 28-days cycles until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
All patients will be closely monitored for safety and tolerability during all cycles of therapy, at the treatment discontinuation visit, and during the follow-up period. The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (v. 5.0) will be used to characterize the toxicity profile of the study treatments on all patients. Patients who discontinue treatment for reasons other than disease progression (e.g., toxicity) will continue scheduled tumor assessments until disease progression, withdrawal of consent, study termination by Sponsor, or death, whichever occurs first. In the absence of disease progression, tumor assessments should continue regardless of whether patients start a new anti-cancer therapy, unless consent is withdrawn. All patients will be followed for survival unless consent is withdrawn.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 68 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial |
| Actual Study Start Date : | October 29, 2019 |
| Actual Primary Completion Date : | May 31, 2022 |
| Actual Study Completion Date : | June 30, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Arm A
Trifluridine-Tipiracil
|
Drug: Trifluridine Tipiracil
Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following: Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest |
|
Experimental: Arm B
Panitumumab + Trifluridine-Tipiracil
|
Drug: Trifluridine Tipiracil
Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following: Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest Drug: Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX] Panitumumab will be administered as a 6 mg/kg intravenous infusion over 60 minutes every 2 weeks (q2w) of a 28-day cycle (Day 1 and Day 15). |
- PFS [ Time Frame: from screening up to 30 months ]PFS: defined as the time from randomization to the earliest documented disease progression or death due to any cause of panitumumab in combination with Trifluridine-Tipiracil vs Trifluridine-Tipiracil"
- ORR [ Time Frame: from screening up to 30 months ]ORR: per the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (v1.1), defined as the number of patients achieving an overall best response of complete or partial response divided by the total number of patients
- OS [ Time Frame: from screening up to 30 months ]OS: defined as the time from randomization to death due to any cause of panitumumab in combination with Trifluridine-Tipiracil vs Trifluridine-Tipiracil
- Safety and tolerability analysis: defined as the evaluation of incidence and severity of AEs, graded according to NCI- CTCAE, version 5.0 (v. 5.0). [ Time Frame: from screening up to 30 months ]To explore the safety and tolerability of panitumumab in combination with Trifluridine-Tipiracil vs standard third line therapy (Trifluridine-Tipiracil)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically proven diagnosis of colorectal adenocarcinoma
- Diagnosis of metastatic disease
- RAS (NRAS and KRAS exon 2,3 and 4) wild-type in tissue at initial diagnosis
- Efficacy of a first line therapy containing an anti-EGFR agent (panitumumab or ceuximab) with a major response achieved (complete or partial response)
- Progression after a second line therapy
- Available and adequate baseline tumour tissue sample
- Measurable disease according to RECIST criteria v1.1
- Male or female patients > 18 years of age
- ECOG Performance Status 0-1
- Life expectancy of at least 3 months
- Adequate bone marrow, liver and renal function
- If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 14 days before initiation of study treatment
- If female and of childbearing potential, or if male, agreement to use adequate contraception (eg, abstinence, intrauterine device, oral contraceptive, or double-barrier method)
- Signed informed consent
Exclusion Criteria:
- Any contraindication to use Trifluridine - Tipiracil or Panitumumab
- More than two previous lines of treatment
- Active uncontrolled infections
- Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix
- Pregnancy
- Breastfeeding
- Interstitial lung disease or pulmonary fibrosis
- Grade III or IV heart failure (NYHA classification)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05468892
| Italy | |
| A.O.U. Cagliari - Presidio Policlinico D. Casula | |
| Monserrato, CA, Italy | |
| A.O.U. Pisana | |
| Pisa, PI, Italy | |
| A.R.N.A.S. Garibaldi - P.O. GaribaldiNesima | |
| Catania, Italy | |
| Istituto Europeo di Oncologia | |
| Milano, Italy | |
| AORN-Ospedale dei colli, UOC Oncologia | |
| Napoli, Italy, 80131 | |
| A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli" | |
| Napoli, Italy | |
| IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" | |
| Napoli, Italy | |
| Universiyà Campus-Biomedico | |
| Roma, Italy | |
| Principal Investigator: | Fortunato Ciardiello | A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli" |
| Responsible Party: | Fortunato Ciardiello, Principle Investigator, University of Campania "Luigi Vanvitelli" |
| ClinicalTrials.gov Identifier: | NCT05468892 |
| Other Study ID Numbers: |
VELO |
| First Posted: | July 21, 2022 Key Record Dates |
| Last Update Posted: | February 1, 2024 |
| Last Verified: | January 2024 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |
Rectal Diseases Trifluridine Panitumumab Antineoplastic Agents, Immunological Antineoplastic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents |